Oral small molecule GLP-1 receptor agonist
Orforglipron 36 mg oral once daily
ORFO_PO_36MG_QD
Related
- All doses pooled: Orforglipron tablet
- Orforglipron 12 mg oral once daily
- Orforglipron 6 mg oral once daily
- Orforglipron 3 mg oral once daily
- Orforglipron maximum tolerated dose tablet once daily
- Orforglipron 1 mg tablet once daily
- Orforglipron 14.5 mg tablet once daily
- Orforglipron 17.2 mg tablet once daily
- Orforglipron 0.8 mg tablet once daily
- Orforglipron 2.5 mg tablet once daily
- Orforglipron 5.5 mg tablet once daily
- Orforglipron 9 mg tablet once daily
- Orforglipron 24 mg oral once daily
- Orforglipron 45 mg oral once daily
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | HbA1c change | weeks 36 to 64 (target week 52) | Placebo | MD -2.04 (-2.39 to -1.61) | 0.88 |
| Type 2 diabetes (adults) | HbA1c change | weeks 36 to 64 (target week 52) | Placebo | MD -1.12 (-1.59 to -0.60) | 0.50 |
| Type 2 diabetes (adults) | HbA1c change | weeks 36 to 64 (target week 52) | Placebo | MD -1.26 (-2.13 to -0.04) | 0.49 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 36 to 64 (target week 52) | Placebo | MD -7.39 (-10.89 to -3.26) | 0.90 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 36 to 64 (target week 52) | Placebo | MD -5.66 (-8.18 to -2.92) | 0.53 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 36 to 64 (target week 52) | Placebo | MD -5.83 (-9.96 to -0.33) | 0.69 |
| Type 2 diabetes (adults) | HbA1c below 7 percent | weeks 36 to 64 (target week 52) | Placebo | OR 5.93 (0.61 to 20.01) | 0.36 |
| Type 2 diabetes (adults) | HbA1c below 7 percent | weeks 36 to 64 (target week 52) | Placebo | OR 5.50 (1.13 to 15.39) | 0.71 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 36 to 64 (target week 52) | Placebo | MD -4.47 (-6.85 to -1.85) | 0.77 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 20 to 36 (target week 26) | Placebo | MD -1.34 (-5.99 to 3.35) | 0.31 |
| Type 2 diabetes (adults) | Percent body weight change | weeks 40 to 104 (target week 68) | Semaglutide 14 mg oral once daily (original tablet) | MD -3.81 (-10.22 to 3.44) | 0.90 |
| Type 2 diabetes (adults) | Percent body weight change | weeks 40 to 104 (target week 68) | Placebo | MD -6.58 (-12.90 to 0.86) | 0.78 |
| Type 2 diabetes (adults) | Weight loss of 5 percent or more | weeks 40 to 104 (target week 68) | Placebo | OR 4.81 (1.41 to 12.84) | 0.72 |
| Type 2 diabetes (adults) | SF-36 physical component summary change | weeks 20 to 130 (target week 52) | Placebo | MD -0.38 (-1.22 to 0.47) | 0.23 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 1.37 (1.01 to 1.88) | 0.31 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 5.04 (3.72 to 6.82) | 0.23 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 7.43 (5.18 to 10.97) | 0.18 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 2.34 (1.82 to 3.01) | 0.31 |
| Type 2 diabetes (adults) | Constipation | longest follow-up | Placebo | HR 3.33 (2.41 to 4.65) | 0.21 |
| Type 2 diabetes (adults) | Acute kidney injury | longest follow-up | Placebo | HR 3.77 (0.31 to 50.02) | 0.22 |
| Overweight or obesity without diabetes (adults) | Systolic blood pressure change | weeks 20 to 40 (target week 26) | Placebo | MD -7.79 (-17.37 to 3.93) | 0.75 |
| Overweight or obesity without diabetes (adults) | Percent body weight change | weeks 40 to 104 (target week 68) | Placebo | MD -11.21 (-17.31 to -2.31) | 0.36 |
| Overweight or obesity without diabetes (adults) | Percent body weight change | weeks 20 to 40 (target week 26) | Placebo | MD -9.39 (-16.57 to -0.67) | 0.60 |
| Overweight or obesity without diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 0.92 (0.47 to 2.01) | 0.58 |
| Overweight or obesity without diabetes (adults) | Nausea | longest follow-up | Placebo | HR 3.80 (2.74 to 5.29) | 0.47 |
| Overweight or obesity without diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 6.55 (3.77 to 10.67) | 0.33 |
| Overweight or obesity without diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 2.19 (1.23 to 3.44) | 0.45 |
| Overweight or obesity without diabetes (adults) | Constipation | longest follow-up | Placebo | HR 3.15 (1.74 to 5.76) | 0.31 |
Trials
- ACHIEVE-3A Phase 3, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Once Daily Oral LY3502970 Compared With Oral Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin (ACHIEVE-3)2023 · 1,698 randomized · 52 weeks
- ATTAIN-2A Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once-Daily Oral LY3502970 Compared With Placebo in Adult Participants With Obesity or Overweight and Type 2 Diabetes (ATTAIN-2)2023 · 1,613 randomized · 72 weeks
- ACHIEVE-5A Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once Daily Oral Orforglipron Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor2023 · 546 randomized · 40 weeks
- ATTAIN-1A Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once-Daily Oral Orforglipron Compared With Placebo in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-1)2023 · 3,127 randomized · 72 weeks
- ACHIEVE-1A Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once Daily Oral LY3502970 Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone2023 · 559 randomized · 40 weeks
- NCT05048719A Phase 2 Study of Once-Daily LY3502970 Compared With Placebo and Once-Weekly Dulaglutide in Participants With Type 2 Diabetes Mellitus2021 · 383 randomized · 26 weeks
- NCT05051579A Phase 2 Study of Once-Daily LY3502970 Compared With Placebo in Participants Who Have Obesity or Are Overweight With Weight-Related Comorbidities2021 · 272 randomized · 36 weeks